Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
QMF149 150/320 · 1 trial · 1 indication
demonstrate the superiority of QMF149 150/80 microgram o.d. (in the evening) delivered via Concept1 compared with MF 200 microgram o.d. (in the evening) delivered via Twisthaler® in terms of trough FEV1 after 12 weeks of treatment in adults and adolescents. Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured by spirometry.
| Arm | Type | Description |
|---|---|---|
| QMF149 150/80 μg | EXPERIMENTAL | QMF149 150/80 microgram o.d. delivered via Concept1 |
| MF 200 µg | ACTIVE_COMPARATOR | MF 200 microgram o.d. delivered via Twisthaler® |
| Name | Type | Description |
|---|---|---|
| QMF149 150/80 μg | DRUG | QMF149 150/80 μg o.d via Concept1 |
| MF 200 μg | DRUG | MF 200 μg o.d. via Twisthaler® |
Inclusion Criteria: * Patients with a documented diagnosis of asthma for a period of at least 3 months prior to Screening Visit * Patients who have used low dose ICS , with or without controller (ie, LABA, Leukotriene Receptor Antagonist ) at stable dose for at least 1 month prior to Screening Visi...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
QMF149 150/320 is an investigational therapy being studied for the treatment of mild asthma. It is a small molecule drug developed by Novartis AG. The Phase 3 trial for this asset enrolled patients with mild asthma, and the program is focused on the respiratory therapeutic area.
QMF149 150/320 is developed by Novartis AG, which trades under the ticker NVS. Novartis is the sponsor of the clinical program evaluating this drug candidate for mild asthma.
QMF149 150/320 is in Phase 3 clinical development. The single Phase 3 trial for this asset has been completed. It is an investigational drug and has not been approved by the FDA for any indication.
QMF149 150/320 has been evaluated in one Phase 3 clinical trial, NCT02892344, titled "Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma." This trial is completed and enrolled 802 patients with mild asthma across multiple countries.